The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

MUZOLIMINE     5-amino-2-[1-(3,4- dichlorophenyl)ethyl]-4H...

Synonyms: Muzolimina, Edrul, Muzoliminum, Bay-g-2821, SureCN123392, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of BAY G 2821

 

Psychiatry related information on BAY G 2821

  • The time-response curve of the increased urine excretion correlated well with the time course of the concentration of muzolimine in plasma [6].
 

High impact information on BAY G 2821

 

Chemical compound and disease context of BAY G 2821

 

Biological context of BAY G 2821

 

Anatomical context of BAY G 2821

  • Muzolimine is a new diuretic which acts on the ascending limb of the loop of Henle and on the distal tubule [14].
  • A series of transport and electrophysiological experiments were carried out on rat salivery duct epithelium to study the mechanism of action of Bay g 2821 on electrolyte transport at the cellular level [16].
  • Muzolimine (10-500 microM) induced a concentration-dependent reduction of both the contractile force and frequency in spontaneously beating atria and in electrically driven left atrium from reserpine-treated guinea pigs [17].
  • We decided to assess the site of action of muzolimine (mucosa versus serosa) by experiments on rats [18].
  • At the 17th minute of stop-flow, placebo (4 animals), furosemide (4 mg i.v. in 5 animals) or muzolimine (1.2 mg i.v. in 5 rats) were injected and three minutes later the renal arteries were clamped bilaterally for 20 minutes [19].
 

Associations of BAY G 2821 with other chemical compounds

 

Gene context of BAY G 2821

  • These are the results: Urinary excretion after the oral administration of muzolimine was within normal limits compared with the literature [21].
  • Since it has been found that muzolimine can increase diuresis even in patients with extremely high uraemia (GFR values less than 5 ml/min), a group of 16 patients (10 haemodialysis patients, HD, and 6 peritoneal dialysis patients, CAPD) was treated daily with 90 mg for a period of one year, commencing with the start of dialysis therapy [23].
 

Analytical, diagnostic and therapeutic context of BAY G 2821

References

  1. Effects of a new loop diuretic (muzolimine) in cirrhosis with ascites: comparison with furosemide. Bernardi, M., De Palma, R., Trevisani, F., Santini, C., Patrono, D., Motta, R., Servadei, D., Gasbarrini, G. Hepatology (1986) [Pubmed]
  2. Comparison of the effects of muzolimine and a fixed combination of diuretics in essential hypertension. Wicker, P., Clementy, J. Clin. Pharmacol. Ther. (1986) [Pubmed]
  3. Muzolimine-induced severe neuromyeloencephalopathy: report of seven cases. Pohlmann-Eden, B., Berlit, P., Maibach, E.A., Gretz, N. Acta neurologica Scandinavica. (1991) [Pubmed]
  4. Diuretic effects of Bay g 2821 in patients with advanced renal failure. Röckel, A. Current medical research and opinion. (1977) [Pubmed]
  5. Pharmacokinetics of Bay g 2821 in the dog and in man. Ritter, W. Current medical research and opinion. (1977) [Pubmed]
  6. Comparison of the pharmacodynamic effects of furosemide and BAY g 2821 and correlation of the pharmacodynamics and pharmacokinetics of BAY g 2821 (muzolimine). Loew, D., Ritter, W., Dycka, J. Eur. J. Clin. Pharmacol. (1977) [Pubmed]
  7. Muzolimine: renal site of action and interaction with probenecid in humans. Noormohamed, F.H., Lant, A.F. Clin. Pharmacol. Ther. (1991) [Pubmed]
  8. Effects of muzolimine on the late distal tubule of necturus kidney. Planelles, G., Meilhac, B., Anagnostopoulos, T. J. Pharmacol. Exp. Ther. (1988) [Pubmed]
  9. Influence of muzolimine on arterial wall elastin. Schmidt, A., Busse, W.D., Garthoff, B., Gau, W., Ritter, W., Wünsche, C., Buddecke, E. Biochem. Pharmacol. (1984) [Pubmed]
  10. Antihypertensive mechanism of the diuretic muzolimine in mild renal failure. Roles of sodium and cardiovascular norepinephrine responsiveness. Schiffl, H., Weidmann, P., Beretta-Piccoli, C., Cottier, C., Seiler, A.J., Ziegler, W.H. Eur. J. Clin. Pharmacol. (1982) [Pubmed]
  11. Treatment of mild to moderate essential hypertension with muzolimine. Two years of follow-up. Amabile, G., Serradimigni, A. Zeitschrift für Kardiologie. (1985) [Pubmed]
  12. Pharmacokinetics of muzolimine after oral administration with and without aluminium hydroxide in healthy volunteers. Ritter, W., Hanisch, M., Lücker, P.W., Venitz, F., Hey, B., Baykal, N. Zeitschrift für Kardiologie. (1985) [Pubmed]
  13. Inhibition of ion transport in Ehrlich cells by muzolimine. Geck, P., Pfeiffer, B. Naunyn Schmiedebergs Arch. Pharmacol. (1986) [Pubmed]
  14. Influence of muzolimine, a new diuretic, on experimental gentamicin nephrotoxicity. Toutain, H., Olier, B., Fillastre, J.P., Morin, J.P. Nephrol. Dial. Transplant. (1987) [Pubmed]
  15. Pharmacokinetics of a single oral dose of muzolimine in cardiac failure. Brørs, O., Jacobsen, S., Arnesen, E. Eur. J. Clin. Pharmacol. (1979) [Pubmed]
  16. Selective blockage of the Na+ transport path by Bay g 2821. Knauf, H., Wais, U., Albiez, G. Current medical research and opinion. (1977) [Pubmed]
  17. Comparison between the cardiac effects induced by muzolimine and furosemide in guinea-pig atria. Dorigo, P., Gaion, R.M., Bergamin, M., Giacometti, A., Valentini, E., Maragno, I. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy. (1990) [Pubmed]
  18. Demonstration of action of muzolimine on the serosal side of Henle's loop cells. Faedda, R., Satta, A., Branca, G.F., Contu, B., Bartoli, E. Zeitschrift für Kardiologie. (1985) [Pubmed]
  19. Prevention of acute renal failure by diuretics. Satta, A., Faedda, R., Turrini, F., Manca, A., Branca, G.F., Bartoli, E. Zeitschrift für Kardiologie. (1985) [Pubmed]
  20. Muzolimine modification of renal vasoconstriction. Steele, T.H., Challoner-Hue, L. Zeitschrift für Kardiologie. (1985) [Pubmed]
  21. Pharmacodynamic and pharmacokinetic correlation of muzolimine with and without aluminium hydroxide. Lücker, P.W., Venitz, J., Hey, B., Baykal, N., Hanisch, M., Ritter, W. Zeitschrift für Kardiologie. (1985) [Pubmed]
  22. Suppression of renin-angiotensin system in the heart of spontaneously hypertensive rats. Rosenthal, J., von Lutterotti, N., Thurnreiter, M., Gomba, S., Rothemund, J., Reiter, W., Kazda, S., Garthoff, B., Jacob, I., Dahlheim, H. Journal of hypertension. Supplement : official journal of the International Society of Hypertension. (1987) [Pubmed]
  23. Muzolimine in patients on chronic hemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD). Bandiani, G., Camaiora, E., Nicolini, M.A., Perotta, U. Zeitschrift für Kardiologie. (1985) [Pubmed]
  24. Determination of muzolimine in plasma and urine by high-performance liquid chromatography. Osman, M.A., Dunning, L.K., Bhavnagri, V.P., Cheng, L.K. J. Chromatogr. (1989) [Pubmed]
  25. Cross-over study of muzolimine and hydrochlorothiazide-amiloride in hypertensive patients. Ferrara, L.A., Strazzullo, P., Scillitani, A., Mancini, M., Gagliardi, R. Eur. J. Clin. Pharmacol. (1985) [Pubmed]
 
WikiGenes - Universities